News & Media

Press releases & statements

Apply filter
Sep 12, 2023
Statement
COVID-19

U.S. CDC and Advisory Committee Recommend Use of Authorized and Approved 2023-2024 Monovalent XBB COVID-19 Vaccines

Read full article
Download
Sep 11, 2023
Statement

Novavax Continues Progress Towards Delivery of its Protein-based Non-mRNA XBB COVID Vaccine to U.S.

Read full article
Download
Jul 24, 2023
Statement

R21/Matrix-M™ Malaria Vaccine Leveraging Novavax’s Adjuvant Technology Gains Additional Authorization

Read full article
Download
Jul 13, 2023
Statement
COVID-19

Novavax Intends to Deliver Protein-based XBB COVID Vaccine as Specified in U.S. HHS Letter to COVID Manufacturers

Read full article
Download
Apr 27, 2023
Statement

PREVENT-19 Adolescent Data Published in the Journal of the American Medical Association Network Open

Read full article
Download
Apr 17, 2023
Statement

Novavax’s Novel Matrix-M™ Adjuvant Technology is Key Component of Oxford Malaria Vaccine

Read full article
Download
Jan 27, 2023
Statement
COVID-19

Novavax Announces Plan to Deliver Updated Protein-based Vaccine Consistent with FDA Recommendations for 2023/2024 Vaccination Season at VRBPAC Meeting

Read full article
Download
Jan 9, 2023
Statement

Novavax to Participate in the 41st Annual J.P. Morgan Healthcare Conference

Read full article
Download
Dec 16, 2022
Statement
COVID-19
Global health

German Health Authority Expands Recommendation for Use of Novavax COVID-19 Vaccine as a Booster

Read full article
Download
Dec 12, 2022
Statement

Swiss and French Health Authorities Expand Recommendations for Use of Nuvaxovid COVID-19 Vaccine as a Booster

Read full article
Download
Showper page